Short answer
TG THERAPEUTICS, INC. (TGTX) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $260M (up 60.7% year over year) with net income of $55M.
Q3 2026 key financials · XBRL
- Revenue
- $260M
- +60.7% YoY · +8.2% QoQ
- Net income
- $55M
- −85.8% YoY · +612.8% QoQ
- Operating margin
- 33.0%
- EPS (diluted)
- $0.35
- −85.5% YoY · +600.0% QoQ
Source: XBRL data from the TG THERAPEUTICS, INC. (TGTX) Q3 2026 10-Q on SEC EDGAR. USD.
TG THERAPEUTICS, INC. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $259.9M, up $98.2M YoY from $161.7M
- BRIUMVI U.S. product revenue $232.6M, up from $152.9M YoY, best-performing product line
- Gross margin 84% versus BRIUMVI U.S. margin 87%; net income $55.5M versus $390.9M
- Nine-month operating cash flow $66.6M versus $(44.4)M YoY; financing provided $291.2M from 2026 Term Loan
- Cash, equivalents and investments $556.7M; liquidity expected to fund operations beyond twelve months
- Near-term headwinds: rising clinical, manufacturing, commercialization and interest expenses; subcutaneous BRIUMVI data expected year-end 2026 or Q1 2027
Risk Factors
- Newly added AI risk: evolving EU AI Act and related rules could increase compliance costs and liability
- Regulatory risk: OBBBA coverage changes and CMS payment pilots could reduce reimbursement for multiple sclerosis medicines
- Operational risk: reliance on Samsung Biologics and FUJIFILM limits BRIUMVI supply resilience
- Competitive risk: faster or more effective rival therapies could reduce BRIUMVI adoption
- Financial risk: $750 million 2026 Term Loan matures March 18, 2031, secured by substantially all assets
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other TG THERAPEUTICS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.